Search results for "Respiratory system"

showing 10 items of 1829 documents

Dose-Related Effect of Beclomethasone Dipropionate on Airway Responsiveness in Asthma

1990

The effects of twice daily inhaled beclomethasone dipropionate (BDP) at two dose levels (500 and 1,000 micrograms daily) on the airway responsiveness to inhaled histamine was evaluated by a randomized, single-blind, cross-over study in 10 patients with stable asthma. The 12-week study began with a 3-week run-in period of baseline treatment, which was continued unchanged throughout the study, and the two treatment periods were separated by a 3-week placebo period. Patients attended the laboratory every 3 weeks for spirometry and histamine inhalation tests to determine the provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 s (PC20 of FEV1). There was a …

AdultMalePulmonary and Respiratory MedicineSpirometryAllergymedicine.drug_classPlaceboRandom Allocationchemistry.chemical_compoundForced Expiratory VolumemedicineHumansLungAsthmaDose-Response Relationship DrugInhalationmedicine.diagnostic_testbusiness.industryAirway ResistanceBeclomethasoneBeclometasone dipropionateMiddle Agedrespiratory systemmedicine.diseaseAsthmachemistryAnesthesiaCorticosteroidFemalebusinessHistamineHistaminemedicine.drugRespiration
researchProduct

The Lack of the Bronchoprotective and Not the Bronchodilatory Ability of Deep Inspiration Is Associated with Airway Hyperresponsiveness

2001

In healthy subjects, deep inspiration (DI) acts both as a bronchodilator and a bronchoprotector. The latter is impaired in asthmatics. We have now evaluated whether the lack of bronchoprotection is related to bronchial hyperresponsiveness (BHR), and whether the bronchodilatory effect is also lost in asthmatics. Ten healthy subjects (PC20 > 75 mg/ml), 12 asthmatics with moderate to severe BHR (PC20 < 1 mg/ml), 14 asthmatics with mild to borderline BHR (1 < PC20 < 25 mg/ml), and 10 rhinitics with mild to borderline BHR (1 < PC20 < 25 mg/ml) underwent single-dose methacholine provocations inducing at least 20% reduction in FEV1 after 20 min of DI inhibition. To measure the bronchodilatory effe…

AdultMalePulmonary and Respiratory MedicineSpirometryRhinitis Allergic Perennialmedicine.drug_classBronchoconstrictionSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineBronchial Provocation TestsFEV1/FVC ratioReference ValuesRisk FactorsForced Expiratory VolumeBronchodilatormedicineHumansReference ValueMethacholine ChlorideAsthmaBronchusmedicine.diagnostic_testbusiness.industryMiddle Agedrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesBronchial Provocation TestBronchodilatationmedicine.anatomical_structureInhalationBronchial hyperresponsivenessAnesthesiaFemaleMethacholineBronchial HyperreactivitybusinessHumancirculatory and respiratory physiologymedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Effect of Salmeterol on Seasonal Changes in Airway Responsiveness and Exhaled Nitric Oxide in Pollen-Sensitive Asthmatic Subjects

2002

Objective Using a model of natural allergen exposure, we examined the effect of regular treatment with salmeterol on allergen-induced changes in airway responsiveness and exhaled nitric oxide (ENO). Design Double-blind, randomized, parallel-group study. Setting Specialist allergy unit in a university hospital. Patients Asthmatic patients sensitized to pollen allergens were randomly allocated to monotherapy with salmeterol (n = 14) or placebo (n = 13). Interventions Salmeterol, 25 μg, and placebo inhalers, two puffs bid, for 6 weeks. Measurements Spirometry, the level of a provocative concentration of a substance (methacholine) causing a 20% fall in FEV 1 (PC 20 ), the PC 20 level for adenos…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicinePlaceboDouble-Blind MethodForced Expiratory VolumeInternal medicineBronchodilatorAdministration InhalationmedicineHumansAlbuterolExpirationSalmeterol XinafoateAsthmamedicine.diagnostic_testbusiness.industryAirway ResistanceRhinitis Allergic SeasonalMiddle Agedrespiratory systemmedicine.diseaseAdenosine MonophosphateAsthmarespiratory tract diseasesEndocrinologyBreath TestsExhaled nitric oxideFemaleMethacholineSeasonsSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

18-yr cumulative incidence of respiratory/allergic symptoms/diseases and risk factors in the Pisa epidemiological study

2019

Abstract Background Few population-based studies on the effects of environmental exposure variation exist. Aim Assessing respiratory symptom/disease incidence related to risk factor exposure changes. Methods A longitudinal general population sample from two surveys (PISA2:1991–1993; PISA3:2009–2011; no. = 970), aged ≥20 years at baseline, completed a questionnaire on respiratory symptoms/diseases, risk factor exposure and performed spirometry. 18-year follow-up cumulative incidence of respiratory symptoms/diseases and longitudinal changes (persistence, incidence, remittance) in risk factor exposure were computed. Results Cumulative incidence values were: 3.2% (corresponding to a 1.8‰/year i…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyTime FactorsAllergyPopulationYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsSurveys and QuestionnairesInternal medicineWheezeTobaccomedicineCOPDHumansCumulative incidence030212 general & internal medicineeducationEnvironmental and occupational Health and EpidemiologyAgedAsthmaCOPDeducation.field_of_studymedicine.diagnostic_testbusiness.industryIncidence (epidemiology)SmokingEnvironmental ExposureEnvironmental exposureMiddle AgedRespiration Disordersmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systemAllergy; Asthma; COPD; Environmental & occupational health and epidemiology; TobaccoFemalemedicine.symptombusinessEnvironmental & occupational health and epidemiologyRespiratory Medicine
researchProduct

The Effect of Spirometry on Bronchial and Alveolar Nitric Oxide in Subjects with Asthma

2013

The effect of spirometric maneuvers on exhaled nitric oxide (NO) at the constant flow rate of 50 ml/s (FE(NO)) has been studied with equivocal results. Furthermore, the effects of spirometry on bronchial NO flux (J'aw(NO)) and alveolar NO (CA(NO)), two measurements increasingly being used in clinical and research protocols, are unknown. The aim of this study was to evaluate the effect of spirometry on FE(NO), J'aw(NO), and CA(NO) in adults with asthma.Forty-four adults with asthma were studied. To assess the impact of exhaled NO measurement itself on exhaled NO values, FE(NO), J'aw(NO), and CA(NO) were obtained twice, at baseline and after a resting period of 10 min. Then spirometry (with o…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtymedicine.drug_classBronchiNitric OxideNitric oxidechemistry.chemical_compoundForced Expiratory VolumeInternal medicineBronchodilatormedicineHumansImmunology and AllergyAsthmamedicine.diagnostic_testConstant flowbusiness.industryrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesPulmonary AlveolichemistrySpirometryPediatrics Perinatology and Child HealthExhaled nitric oxideCardiologyFemalebusinessJournal of Asthma
researchProduct

Effects of Inhaled Fenoterol on the Circadian Rhythm of Expiratory Flow in Allergic Bronchial Asthma

1983

Metered-dose aerosol treatment with fenoterol for three consecutive days, in eight patients suffering from allergic asthma, caused the disappearance of FEV1 and MEF50 circadian rhythm. We attribute such behavior to the suppression of the bronchomotor tone induced by fenoterol. The administration on different days of a single dose of fenoterol aerosol in another group of eight patients pointed out the variability of the effects of the drug at different hours of the day. We believe the results obtained are important for a better dosage and time distribution of the therapy with beta2 agonists.

AdultMalePulmonary and Respiratory MedicineTime distributionMaximal Midexpiratory Flow RateCritical Care and Intensive Care MedicinemedicineHumansCircadian rhythmFenoterolFenoterolAsthmaAerosolsbusiness.industryAllergic asthmaForced Expiratory Flow RatesMaximal midexpiratory flow raterespiratory systemmedicine.diseaseAsthmaCircadian RhythmForced Expiratory Flow RatesB2 receptorEthanolaminesAnesthesiaFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Depression is associated with poor control of symptoms in asthma and rhinitis: A population-based study

2019

Abstract Background Although many studies have highlighted the link between asthma/rhinitis and depression, it is still unclear which characteristics of these diseases are associated with the risk of depression. We aimed to explore the relationship between depression and asthma or rhinitis in a representative sample of the Italian general population. Methods The data were collected in GEIRD, an Italian multicenter, population-based, multicase-control study. 2227 participants (age 21–86 years, female 50%) underwent standardized interviews, skin prick and lung function tests, and were divided into cases of current asthma (n = 528), rhinitis without asthma (n = 972), and controls (n = 727). Tw…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyActivities of daily livingPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingAtopyYoung Adult03 medical and health sciences0302 clinical medicineAsthma controlInternal medicinemedicineHumans030212 general & internal medicineMedical prescriptioneducationAgedRhinitisAsthmaAged 80 and overeducation.field_of_studyAtopyDepressionbusiness.industryAnhedoniaGeneral populationMiddle Agedmedicine.diseaseAsthmaPatient Health QuestionnaireItaly030228 respiratory systemAsthma control; Atopy; Depression; General population; Rhinitis controlRhinitis controlFemalemedicine.symptombusinessRespiratory Medicine
researchProduct

Lack of association of Aspergillus colonization with the development of bronchiolitis obliterans syndrome in lung transplant recipients: An internati…

2019

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is a major limitation in the long-term survival of lung transplant recipients (LTRs). However, the risk factors in the development of BOS remain undetermined. We conducted an international cohort study of LTRs to assess whether Aspergillus colonization with large or small conidia is a risk factor for the development of BOS.METHODS: Consecutive LTRs from January 2005 to December 2008 were evaluated. Rates of BOS and associated risk factors were recorded at 4 years. International Society of Heart and Lung Transplantation criteria were used to define fungal and other infections. A Cox proportional-hazards-model was constructed to assess the a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentInternational Cooperationmedicine.medical_treatmentBronchiolitis obliterans030230 surgeryCohort StudiesYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLung transplantationBOSCumulative incidenceRisk factorBronchiolitis ObliteransTransplantationbusiness.industryHazard ratioMiddle Agedcolonizationmedicine.diseasehumanitiesBOS; aspergillus; colonization; lung transplantation; risk factorsTransplantationAspergillus030228 respiratory systemCohortFemaleSurgeryCardiology and Cardiovascular MedicinebusinessLung TransplantationCohort studyThe Journal of Heart and Lung Transplantation
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology &amp; Therapeutics
researchProduct